Atlas Trials

Refractory Marginal Zone Lymphoma

19 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Refractory Marginal Zone Lymphoma

RecordFirmDate
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (NCT04836832)Narendranath Epperla2022-07-01
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (NCT05025800)M.D. Anderson Cancer Center2021-10-13
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (NCT04995536)City of Hope Medical Center2021-07-27
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633)Fred Hutchinson Cancer Center2021-01-25
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma (NCT04578600)Joseph Tuscano2020-10-23
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment (NCT04447716)Thomas Jefferson University2020-10-16
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies (NCT04205409)University of Washington2020-06-05
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT03583424)Ohio State University Comprehensive Cancer Center2018-09-10
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (NCT03479268)City of Hope Medical Center2018-04-27
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729)Fred Hutchinson Cancer Center2017-12-05
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (NCT02568553)National Cancer Institute (NCI)2016-11-15
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma (NCT01995669)M.D. Anderson Cancer Center2014-05-27
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT01955499)National Cancer Institute (NCI)2013-09-24
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma (NCT01381692)National Cancer Institute (NCI)2011-07-20

Track Refractory Marginal Zone Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.